Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591.
Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Bayer is directing investor attention back to its pharmaceutical development pipeline with a strategic move that signals more than just business as usual. The f ...
Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...
Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results